{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:05:49Z","timestamp":1789725949675,"version":"4.0.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031585","name":"Takeda Development Center Americas, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031585","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A discrete choice experiment (DCE) subsequently incorporated into a multi-criteria decision analysis (MCDA) was used to compare clinicians\u2019 trade-offs between the benefits and risks of preemptive anti-cytomegalovirus (CMV) treatments posthematopoietic cell transplant (HCT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the DCE, physicians completed forced-choice tasks comparing hypothetical treatments. We used logit models to estimate preference weights, relative attribute importance (RAI) score, and minimum acceptable benefit. The MCDA combined DCE-derived weighted attributes with clinical performance data to compare maribavir versus valganciclovir (using data from the AURORA study) and maribavir versus valganciclovir, ganciclovir, and foscarnet (using data from multiple sources). Analyses were conducted for 2 cohorts defined by baseline absolute neutrophil count (ANC) &amp;lt;1500\/mm3 or \u22651500\/mm3 at CMV reactivation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the DCE, all 7 attributes significantly impacted physician (n = 377) treatment choices; the most important were administration route\/monitoring (RAI score = 25.7%), nephrotoxicity risk (RAI score = 18.5%), grade 3\u20134 neutropenia risk (RAI score = 18.1%), and week 8 viremia clearance (RAI score = 16.0%). Neutropenia at CMV reactivation significantly reduced physicians\u2019 preference for treatments with a higher grade 3\u20134 neutropenia risk. In the MCDA, overall benefit\u2013risk scores were higher for maribavir than valganciclovir in both ANC cohorts. Among the considered attributes, the largest positive contributor to the overall benefit\u2013risk score was viremia clearance at week 8, and the largest negative contributor was grade 3\u20134 neutropenia risk. Maribavir had a higher overall benefit\u2013risk score than ganciclovir and foscarnet in both ANC cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Within this MCDA framework, maribavir was preferred over valganciclovir, ganciclovir, and foscarnet for preemptive treatment of CMV after HCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag500","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:43:34Z","timestamp":1788273814000},"source":"Crossref","is-referenced-by-count":0,"title":["Multi-Criteria Decision Analysis using Physician Preferences from a Global Discrete Choice Experiment to Investigate the Selection of Preemptive Antiviral Treatments for Post-Hematopoietic Cell Transplant Cytomegalovirus Infection"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"first","affiliation":[{"name":"Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]},{"name":"Department of Medicine, Weill Cornell Medical College , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4182-341X","authenticated-orcid":false,"given":"Jo-Anne H","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Minnesota , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommi","family":"Tervonen","sequence":"additional","affiliation":[{"name":"Kielo Research , Zug ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Deparis","sequence":"additional","affiliation":[{"name":"Kielo Research , Zug ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6275-8747","authenticated-orcid":false,"given":"Jonathan D","family":"Norton","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Gugiu","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien","family":"Bo","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Davis","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShunPing","family":"Quan","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4567-702X","authenticated-orcid":false,"given":"Victoria L","family":"Prince","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Abou Ali","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8247-7889","authenticated-orcid":false,"given":"Jessica","family":"Auciello","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"2026091805321018700_ofag500-B1","doi-asserted-by":"crossref","first-page":"106860","DOI":"10.1016\/j.ijantimicag.2023.106860","article-title":"Management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplants","volume":"62","author":"Allaw","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026091805321018700_ofag500-B2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","article-title":"American Society for Transplantation and Cellular Therapy series: #3-Prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation","volume":"27","author":"Hakki","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2026091805321018700_ofag500-B3","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2026091805321018700_ofag500-B4","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/tid.12456","article-title":"Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration","volume":"17","author":"Takahata","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"2026091805321018700_ofag500-B5","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.bbmt.2020.03.019","article-title":"Impact of preemptive therapy for cytomegalovirus on toxicities after allogeneic hematopoietic cell transplantation in clinical practice: a retrospective single-center cohort study","volume":"26","author":"Zavras","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026091805321018700_ofag500-B6","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"key":"2026091805321018700_ofag500-B7","author":"Takeda Pharmaceuticals America Inc"},{"key":"2026091805321018700_ofag500-B8","author":"Takeda Pharmaceuticals Australia Pty Ltd"},{"key":"2026091805321018700_ofag500-B9","author":"Takeda Pharmaceuticals International AG Ireland Branch"},{"key":"2026091805321018700_ofag500-B10","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026091805321018700_ofag500-B11","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/cid\/ciad709","article-title":"Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir","volume":"78","author":"Papanicolaou","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026091805321018700_ofag500-B12","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40273-014-0170-x","article-title":"Discrete choice experiments in health economics: a review of the literature","volume":"32","author":"Clark","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"2026091805321018700_ofag500-B13","doi-asserted-by":"crossref","first-page":"102965","DOI":"10.1016\/j.eclinm.2024.102965","article-title":"Prediction accuracy of discrete choice experiments in health-related research: a systematic review and meta-analysis","volume":"79","author":"Zhang","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026091805321018700_ofag500-B14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12911-018-0663-1","article-title":"Multicriteria decision analysis (MCDA) in health care: a systematic review of the main characteristics and methodological steps","volume":"18","author":"Fraz\u00e3o","year":"2018","journal-title":"BMC Med Inform Decis Mak"},{"key":"2026091805321018700_ofag500-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jval.2015.12.003","article-title":"Multiple criteria decision analysis for health care decision making\u2014an introduction: report 1 of the ISPOR MCDA emerging good practices task force","volume":"19","author":"Thokala","year":"2016","journal-title":"Value Health"},{"key":"2026091805321018700_ofag500-B16","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s41669-024-00510-w","article-title":"Clinicians\u2019 preferences for sphingosine-1-phosphate receptor modulators in multiple sclerosis based on clinical management considerations: a choice experiment","volume":"8","author":"Keenan","year":"2024","journal-title":"Pharmacoecon Open"},{"key":"2026091805321018700_ofag500-B17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jval.2022.12.006","article-title":"Quantitative benefit-risk assessment in medical product decision making: a good practices report of an ISPOR task force","volume":"26","author":"Tervonen","year":"2023","journal-title":"Value Health"},{"key":"2026091805321018700_ofag500-B18","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40273-017-0506-4","article-title":"Discrete choice experiments: a guide to model specification, estimation and software","volume":"35","author":"Lancsar","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"2026091805321018700_ofag500-B19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00133443","article-title":"The structure of random utility models","volume":"8","author":"Manski","year":"1977","journal-title":"Theor Decis"},{"key":"2026091805321018700_ofag500-B20","author":"McFadden"},{"key":"2026091805321018700_ofag500-B21","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2307\/1924536","article-title":"On approximating the statistical properties of elasticities","volume":"68","author":"Krinsky","year":"1986","journal-title":"Rev Econ Stat"},{"key":"2026091805321018700_ofag500-B22","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S1098-3597(06)80053-0","article-title":"Neutropenia: etiology and pathogenesis","volume":"8 Suppl 5","author":"Schwartzberg","year":"2006","journal-title":"Clin Cornerstone"},{"key":"2026091805321018700_ofag500-B23","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.bbmt.2017.11.038","article-title":"Impact of cytomegalovirus viral load on probability of spontaneous clearance and response to preemptive therapy in allogeneic stem cell transplantation recipients","volume":"24","author":"Camargo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026091805321018700_ofag500-B24","doi-asserted-by":"crossref","first-page":"ofaf612","DOI":"10.1093\/ofid\/ofaf612","article-title":"Cytomegalovirus viral load continues to predict poor outcomes in adults and children despite improved hematopoietic cell transplantation success","volume":"12","author":"Sadowska-Klasa","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026091805321018700_ofag500-B25","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1182\/blood.V90.6.2502","article-title":"Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome","volume":"90","author":"Salzberger","year":"1997","journal-title":"Blood"},{"key":"2026091805321018700_ofag500-B26","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.5001\/omj.2023.113","article-title":"Cytomegalovirus infection post-hematopoietic stem cell transplant: incidence, risk factors, and outcome in an Omani cohort","volume":"38","author":"Al Farsi","year":"2023","journal-title":"Oman Med J"},{"key":"2026091805321018700_ofag500-B27","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.bbmt.2020.05.007","article-title":"Treatment with foscarnet after allogeneic hematopoietic cell transplant (Allo-HCT) is associated with long-term loss of renal function","volume":"26","author":"Foster","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026091805321018700_ofag500-B28","doi-asserted-by":"crossref","first-page":"934607","DOI":"10.3389\/froh.2022.934607","article-title":"Taste and smell disturbances in patients with chronic oral graft vs. Host disease: an observational study","volume":"3","author":"Boor","year":"2022","journal-title":"Front Oral Health"},{"key":"2026091805321018700_ofag500-B29","first-page":"687","article-title":"Taste alterations after hematopoietic cell transplantation: a scoping review","volume":"32","author":"Dequae","year":"2024","journal-title":"Support Care Cancer"},{"key":"2026091805321018700_ofag500-B30","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bbmt.2017.10.022","article-title":"Unlocking the Complex flavors of dysgeusia after hematopoietic cell transplantation","volume":"24","author":"Scordo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026091805321018700_ofag500-B31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/13696998.2022.2046388","article-title":"Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation","volume":"25","author":"Cheng","year":"2022","journal-title":"J Med Econ"},{"key":"2026091805321018700_ofag500-B32","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.tra.2013.12.010","article-title":"Hypothetical bias in stated choice experiments: is it a problem? And if so, how do we deal with it?","volume":"61","author":"Fifer","year":"2014","journal-title":"Transp Res Part A Policy Pract"},{"key":"2026091805321018700_ofag500-B33","doi-asserted-by":"crossref","first-page":"112736","DOI":"10.1016\/j.socscimed.2019.112736","article-title":"Can healthcare choice be predicted using stated preference data?","volume":"246","author":"de Bekker-Grob","year":"2020","journal-title":"Soc Sci Med"},{"key":"2026091805321018700_ofag500-B34","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/1120009X.2021.1915074","article-title":"Relationship between renal dysfunction and electrolyte abnormalities in hematopoietic stem cell transplant patients treated with foscarnet","volume":"33","author":"Ota","year":"2021","journal-title":"J Chemother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag500\/70894332\/ofag500.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag500\/70894332\/ofag500.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:33:07Z","timestamp":1789723987000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag500\/8778552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag500","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,9,1]]},"article-number":"ofag500"}}